On Haag Duality for Pure States of Quantum Spin Chain

We consider quantum spin chains and their translationally invariant pure states. We prove Haag duality for quasilocal observables localized in semi-infinite intervals when the von Neumann algebras generated by observables localized in these intervals are not type I

On the structure of Clifford quantum cellular automata

We study reversible quantum cellular automata with the restriction that these are also Clifford operations. This means that tensor products of Pauli operators (or discrete Weyl operators) are mapped to tensor products of Pauli operators. Therefore Clifford quantum cellular automata are induced by symplectic cellular automata in phase space. We characterize these symplectic cellular automata and find that all possible local rules must be, up to some global shift, reflection invariant with respect to the origin. In the one dimensional case we also find that every uniquely determined and translationally invariant stabilizer state can be prepared from a product state by a single Clifford cellular automaton timestep, thereby characterizing these class of stabilizer states, and we show that all 1D Clifford quantum cellular automata are generated by a few elementary operations. We also show that the correspondence between translationally invariant stabilizer states and translationally invariant Clifford operations holds for periodic boundary conditions.Comment: 28 pages, 2 figures, LaTe

Semicausal operations are semilocalizable

We prove a conjecture by DiVincenzo, which in the terminology of Preskill et al. [quant-ph/0102043] states that ``semicausal operations are semilocalizable''. That is, we show that any operation on the combined system of Alice and Bob, which does not allow Bob to send messages to Alice, can be represented as an operation by Alice, transmitting a quantum particle to Bob, and a local operation by Bob. The proof is based on the uniqueness of the Stinespring representation for a completely positive map. We sketch some of the problems in transferring these concepts to the context of relativistic quantum field theory.Comment: 4 pages, 1 figure, revte

Diabetes changes ionotropic glutamate receptor subunit expression level in the human retina

Early diabetic retinopathy is characterized by changes in subtle visual functions such as contrast sensitivity and dark adaptation. The outcome of several studies suggests that glutamate is involved in retinal neurodegeneration during diabetes. We hypothesized that the protein levels of ionotropic glutamate receptor subunits are altered in the retina during diabetes. Therefore, we investigated whether human diabetic patients have altered immunoreactivity of ionotropic glutamate receptor subunits in the retina.http://www.sciencedirect.com/science/article/B6SYR-4RS9SS1-1/1/232d6ae7147919a2286326863ee69f1

Entanglement on mixed stabilizer states: normal forms and reduction procedures

Published versio

Reexamination of Quantum Bit Commitment: the Possible and the Impossible

Bit commitment protocols whose security is based on the laws of quantum mechanics alone are generally held to be impossible. In this paper we give a strengthened and explicit proof of this result. We extend its scope to a much larger variety of protocols, which may have an arbitrary number of rounds, in which both classical and quantum information is exchanged, and which may include aborts and resets. Moreover, we do not consider the receiver to be bound to a fixed "honest" strategy, so that "anonymous state protocols", which were recently suggested as a possible way to beat the known no-go results are also covered. We show that any concealing protocol allows the sender to find a cheating strategy, which is universal in the sense that it works against any strategy of the receiver. Moreover, if the concealing property holds only approximately, the cheat goes undetected with a high probability, which we explicitly estimate. The proof uses an explicit formalization of general two party protocols, which is applicable to more general situations, and a new estimate about the continuity of the Stinespring dilation of a general quantum channel. The result also provides a natural characterization of protocols that fall outside the standard setting of unlimited available technology, and thus may allow secure bit commitment. We present a new such protocol whose security, perhaps surprisingly, relies on decoherence in the receiver's lab.Comment: v1: 26 pages, 4 eps figures. v2: 31 pages, 5 eps figures; replaced with published version; title changed to comply with puzzling Phys. Rev. regulations; impossibility proof extended to protocols with infinitely many rounds or a continuous communication tree; security proof of decoherence monster protocol expanded; presentation clarifie

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Drug combinations can improve angiostatic cancer treatment efficacy and enable the reduction of side effects and drug resistance. Combining drugs is non-trivial due to the high number of possibilities. We applied a feedback system control (FSC) technique with a population-based stochastic search algorithm to navigate through the large parametric space of nine angiostatic drugs at four concentrations to identify optimal low-dose drug combinations. This implied an iterative approach of in vitro testing of endothelial cell viability and algorithm-based analysis. The optimal synergistic drug combination, containing erlotinib, BEZ-235 and RAPTA-C, was reached in a small number of iterations. Final drug combinations showed enhanced endothelial cell specificity and synergistically inhibited proliferation (p < 0.001), but not migration of endothelial cells, and forced enhanced numbers of endothelial cells to undergo apoptosis (p < 0.01). Successful translation of this drug combination was achieved in two preclinical in vivo tumor models. Tumor growth was inhibited synergistically and significantly (p < 0.05 and p < 0.01, respectively) using reduced drug doses as compared to optimal single-drug concentrations. At the applied conditions, single-drug monotherapies had no or negligible activity in these models. We suggest that FSC can be used for rapid identification of effective, reduced dose, multi-drug combinations for the treatment of cancer and other diseases

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME):The BRDME Study, a Randomized Trial

Purpose: To generate conclusive evidence regarding the noninferiority of intravitreal bevacizumab compared with ranibizumab in patients with diabetic macular edema (DME). Design: Comparative, randomized, double-masked, multicenter, noninferiority clinical trial. Participants: Eligible patients were older than 18 years, diagnosed with type 1 or type 2 diabetes mellitus, with glycosylated hemoglobin of less than 12%, central area thickness of more than 325 μm, and visual impairment from DME with a best-corrected visual acuity (BCVA) between 24 letters and 78 letters. Methods: From June 2012 through February 2018, a total of 170 participants were randomized to receive 6 monthly injections of either 1.25 mg bevacizumab (n = 86) or 0.5 mg ranibizumab (n = 84). Main Outcome Measures: Primary outcome was change in BCVA from baseline to month 6 compared between the 2 treatment arms. The noninferiority margin was 3.5 letters. Results: The difference in mean BCVA between treatment arms was 1.8 letters in favor of ranibizumab after 6 months of follow-up; BCVA improved by 4.9±6.7 letters in the bevacizumab group and 6.7±8.7 letters in the ranibizumab group. The lower bound of the 2-sided 90% confidence interval (CI) was –3.626 letters, exceeding the noninferiority margin of 3.5 letters. Central area thickness decreased more with ranibizumab (138.2±114.3 μm) compared with bevacizumab (64.2±104.2 μm). In a post hoc subgroup analysis, participants with a worse BCVA at baseline (≤69 letters) improved by 6.7±7.0 letters with bevacizumab and 10.4±10.0 letters with ranibizumab, and central area thickness decreased significantly more in the ranibizumab arm of this subgroup compared with the bevacizumab arm. Participants with an initially better BCVA at baseline (≥70 letters) did not demonstrate differences in BCVA or OCT outcomes between treatment arms. Conclusions: Based on change in BCVA from baseline to month 6, the noninferiority of 1.25 mg bevacizumab to 0.5 mg ranibizumab was not confirmed. Only the subgroup of patients with a lower BCVA at baseline showed better visual acuity and anatomic outcomes with ranibizumab. Our study confirmed the potential differential efficacy of anti–vascular endothelial growth factor agents in the treatment of DME as well as the difference in response between patient groups with different baseline visual acuities